(IN BRIEF) WACKER has launched a new Contract Research Services platform designed to support biotech and biopharma companies developing nucleic acid-based medicines, including RNA therapies, plasmid DNA technologies and lipid nanoparticle formulations. Operating from the company’s Biotechnology Center in Munich, … Read the full press release
Posted in Business, Chemicals, Economy, Financial, Germany, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged advanced therapeutics, biopharma, biotechnology, biotechnology innovation, biotechnology research, circular RNA, clinical manufacturing, Contract Research Services, crs, drug development, gene therapy, GMP manufacturing, lipid nanoparticles, LNPs, mRNA, Munich, nucleic acid medicines, pDNA, pharmaceutical industry, plasmid DNA, PLASMITEC®, RNA engineering, RNA therapeutics, saRNA, self-amplifying RNA, SRTD Biotech GmbH, vaccine development, WACKER, Wacker Biotech, WACKER expands advanced therapeutics capabilities with integrated Contract Research Services offering, WACKER expands biotechnology services with new Contract Research Services platform for nucleic acid medicines, WACKER launches new biotechnology research platform for RNA and nucleic acid therapeutic development, WACKER strengthens global biotechnology services with scalable nucleic acid development solutions
(PRESS RELEASE) MUNICH/ HALLE, PLANKSTADT, 11-Apr-2022 — /EuropaWire/ — WACKER Group (ETR: WCH), a German multinational chemical company, and CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), have announced that their joint bid to … Read the full press release
Posted in Chemicals, Germany, Government, Healthcare, News, Pharma & Biotech, Technology
Tagged biotech site, Christian Hartel, CordenPharma, coronavirus pandemic, lipid nanoparticles, LNP, messenger ribonucleic acid, Michael Quirmbach, mRNA, pDNA, plasmid DNA, Susanne Leonhartsberger, vaccine, WACKER, Weinberg Campus
(PRESS RELEASE) MELBOURNE, Australia, 3-Feb-2022 — /EuropaWire/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged AAVs, adeno-associated viral vectors, Arch Ventures, Australian technologist, Biotech, Codiak Biociences, Daisy Scarborough, DNA/RNA, Dr Ian Dixon, Evox Therapeutics, EVPS, Exopharm, Exoria, exosome therapeutics, exosomes, gene therapies, genetic disorders, LEAP™, lipid nanoparticles, LNPs, LOAD, Lonza, medicine, Pharmaceutical, vaccines
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?